Log In
BCIQ
Print this Print this
 

SPK-9001, SPK-FIX

  Manage Alerts
Collapse Summary General Information
Company Spark Therapeutics Inc.
DescriptionAdeno-associated virus (AAV) that delivers the Factor IX gene to the liver
Molecular Target Factor IX
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPhase I/II
Standard IndicationHemophilia
Indication DetailsTreat hemophilia B
Regulatory Designation U.S. - Breakthrough Therapy (Treat hemophilia B)
PartnerPfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$280.0M

$20.0M

$260.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/08/2014

$280.0M

$20.0M

$260.0M

Get a free BioCentury trial today